Scarinci Hollenbeck, LLC, LLCScarinci Hollenbeck, LLC, LLC

Firm Insights

SCOTUS Clarifies Scope of On-Sale Bar

Author: Scarinci Hollenbeck, LLC

Date: May 24, 2019

Key Contacts

Back

The U.S. Supreme Court Recently Clarified the Scope of the On-Sale Bar Ruling That Secret Sales Can Invalidate Patent

The on-sale bar, a long-standing principle of U.S. patent law, provides that an invention is ineligible for patent protection if it has been offered for sale for over one year prior to the patent filing.

SCOTUS Clarifies Scope of On-Sale Bar

In Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc., the U.S. Supreme Court unanimously held that the passage of the Leahy-Smith America Invents Act (AIA) did not alter prior precedent regarding the on-sale bar. Specifically, the Court ruled that “a commercial sale to a third party who is required to keep the invention confidential may place the invention ‘on sale’ under the AIA”.

Facts of Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc.

The AIA also redefined prior art, including the on-sale bar. As amended by the AIA, 35 U.S.C. 102(b) now states:

A person shall be entitled to a patent unless— (1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention.

The key issue before the Supreme Court was whether the insertion of the language “otherwise available to the public” altered the application of the on-sale bar. Petitioner Helsinn Healthcare S.A. (Helsinn) argued that the phrase limits the scope of the on-sale bar to only cover publicly available sales activity, a view which was supported by the U.S. Patent and Trademark Office (USPTO). Under its revised guidelines to patent examiners following enactment of the AIA, the USPTO explained, sales “among individuals having an obligation of confidentiality to the inventor” did not constitute prior art under the AIA.

The Federal Circuit disagreed. It held that the public disclosure of the existence of a commercial sale invalidates a patent, even if the claimed invention itself remains secret and is not available to the public.  “[T]he asserted claims of the patents-in-suit were subject to an invalidating contract for sale prior to the critical date of January 30, 2002, and the AIA did not change the statutory meaning of ‘on sale’ in the circumstances involved here,” the appeals court wrote.

Supreme Court’s Decision in Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc.

The Supreme Court upheld the Federal Circuit’s decision, concluding that inventor’s sale of an invention to a third party that was obligated to keep the invention confidential qualified as prior art for purposes of determining the patentability of the invention. Justice Clarence Thomas wrote on behalf of the unanimous Court.

In reaching its decision, the Court noted that every patent statute since 1836 has included an on-sale bar. It also emphasized that its own precedent interpreting the pre-AIA on-sale bar provision supports the view that a sale or offer of sale need not make an invention available to the public to constitute invalidating prior art. “The Federal Circuit—which has ‘exclusive jurisdiction’ over patent appeals, 28 U. S. C. §1295(a)—has made explicit what was implicit in our precedents,” Justice Thomas added. “It has long held that ‘secret sales’ can invalidate a patent.”

The Court further concluded that the catch-all phrase “or otherwise available to the public” did not alter its conclusion. Justice Thomas explained:

As amicus United States noted at oral argument, if “on sale” had a settled meaning before the AIA was adopted, then adding the phrase “or otherwise available to the public” to the statute “would be a fairly oblique way of attempting to overturn” that “settled body of law.” Tr. of Oral Arg. 28. The addition of “or otherwise available to the public” is simply not enough of a change for us to conclude that Congress intended to alter the meaning of the reenacted term “on sale.”

Key Takeaway

The Supreme Court’s decision makes it even more imperative for businesses to thoroughly review the structure of joint ventures and other development deals with an experienced intellectual property attorney to verify that the agreements can’t later be interpreted as an offer to sell a later-patented invention. As highlighted by the Court’s ruling, simply including confidentiality provisions in such agreements won’t shield the invention from invalidation under the on-sale bar. 

If you have questions, please contact us

If you have any questions or if you would like to discuss the matter further, please contact me, David A. Einhorn, at 201-806-3364.

No Aspect of the advertisement has been approved by the Supreme Court. Results may vary depending on your particular facts and legal circumstances.

Scarinci Hollenbeck, LLC, LLC

Related Posts

See all
Does Your Homeowners Insurance Provide Adequate Coverage? post image

Does Your Homeowners Insurance Provide Adequate Coverage?

Your home is likely your greatest asset, which is why it is so important to adequately protect it. Homeowners insurance protects you from the financial costs of unforeseen losses, such as theft, fire, and natural disasters, by helping you rebuild and replace possessions that were lost While the definition of “adequate” coverage depends upon a […]

Author: Jesse M. Dimitro

Link to post with title - "Does Your Homeowners Insurance Provide Adequate Coverage?"
Understanding the Importance of a Non-Contingent Offer post image

Understanding the Importance of a Non-Contingent Offer

Making a non-contingent offer can dramatically increase your chances of securing a real estate transaction, particularly in competitive markets like New York City. However, buyers should understand that waiving contingencies, including those related to financing, or appraisals, also comes with significant risks. Determining your best strategy requires careful analysis of the property, the market, and […]

Author: Jesse M. Dimitro

Link to post with title - "Understanding the Importance of a Non-Contingent Offer"
Fred D. Zemel Appointed Chair of Strategic Planning at Scarinci & Hollenbeck, LLC post image

Fred D. Zemel Appointed Chair of Strategic Planning at Scarinci & Hollenbeck, LLC

Business Transactional Attorney Zemel to Spearhead Strategic Initiatives for Continued Growth and Innovation Little Falls, NJ – February 21, 2025 – Scarinci & Hollenbeck, LLC is pleased to announce that Partner Fred D. Zemel has been named Chair of the firm’s Strategic Planning Committee. In this role, Mr. Zemel will lead the committee in identifying, […]

Author: Scarinci Hollenbeck, LLC

Link to post with title - "Fred D. Zemel Appointed Chair of Strategic Planning at Scarinci & Hollenbeck, LLC"
Novation Agreement Process: Step-by-Step Guide for Businesses post image

Novation Agreement Process: Step-by-Step Guide for Businesses

Big changes sometimes occur during the life cycle of a contract. Cancelling a contract outright can be bad for your reputation and your bottom line. Businesses need to know how to best address a change in circumstances, while also protecting their legal rights. One option is to transfer the “benefits and the burdens” of a […]

Author: Dan Brecher

Link to post with title - "Novation Agreement Process: Step-by-Step Guide for Businesses"
What Is a Trade Secret? Key Elements and Legal Protections Explained post image

What Is a Trade Secret? Key Elements and Legal Protections Explained

What is a trade secret and why you you protect them? Technology has made trade secret theft even easier and more prevalent. In fact, businesses lose billions of dollars every year due to trade secret theft committed by employees, competitors, and even foreign governments. But what is a trade secret? And how do you protect […]

Author: Ronald S. Bienstock

Link to post with title - "What Is a Trade Secret? Key Elements and Legal Protections Explained"
What Is Title Insurance? Safeguarding Against Title Defects post image

What Is Title Insurance? Safeguarding Against Title Defects

If you are considering the purchase of a property, you may wonder — what is title insurance, do I need it, and why do I need it? Even seasoned property owners may question if the added expense and extra paperwork is really necessary, especially considering that people and entities insured by title insurance make fewer […]

Author: Patrick T. Conlon

Link to post with title - "What Is Title Insurance? Safeguarding Against Title Defects"

No Aspect of the advertisement has been approved by the Supreme Court. Results may vary depending on your particular facts and legal circumstances.

Sign up to get the latest from our attorneys!

Explore What Matters Most to You.

Consider subscribing to our Firm Insights mailing list by clicking the button below so you can keep up to date with the firm`s latest articles covering various legal topics.

Stay informed and inspired with the latest updates, insights, and events from Scarinci Hollenbeck. Our resource library provides valuable content across a range of categories to keep you connected and ahead of the curve.

SCOTUS Clarifies Scope of On-Sale Bar

Author: Scarinci Hollenbeck, LLC

The U.S. Supreme Court Recently Clarified the Scope of the On-Sale Bar Ruling That Secret Sales Can Invalidate Patent

The on-sale bar, a long-standing principle of U.S. patent law, provides that an invention is ineligible for patent protection if it has been offered for sale for over one year prior to the patent filing.

SCOTUS Clarifies Scope of On-Sale Bar

In Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc., the U.S. Supreme Court unanimously held that the passage of the Leahy-Smith America Invents Act (AIA) did not alter prior precedent regarding the on-sale bar. Specifically, the Court ruled that “a commercial sale to a third party who is required to keep the invention confidential may place the invention ‘on sale’ under the AIA”.

Facts of Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc.

The AIA also redefined prior art, including the on-sale bar. As amended by the AIA, 35 U.S.C. 102(b) now states:

A person shall be entitled to a patent unless— (1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention.

The key issue before the Supreme Court was whether the insertion of the language “otherwise available to the public” altered the application of the on-sale bar. Petitioner Helsinn Healthcare S.A. (Helsinn) argued that the phrase limits the scope of the on-sale bar to only cover publicly available sales activity, a view which was supported by the U.S. Patent and Trademark Office (USPTO). Under its revised guidelines to patent examiners following enactment of the AIA, the USPTO explained, sales “among individuals having an obligation of confidentiality to the inventor” did not constitute prior art under the AIA.

The Federal Circuit disagreed. It held that the public disclosure of the existence of a commercial sale invalidates a patent, even if the claimed invention itself remains secret and is not available to the public.  “[T]he asserted claims of the patents-in-suit were subject to an invalidating contract for sale prior to the critical date of January 30, 2002, and the AIA did not change the statutory meaning of ‘on sale’ in the circumstances involved here,” the appeals court wrote.

Supreme Court’s Decision in Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc.

The Supreme Court upheld the Federal Circuit’s decision, concluding that inventor’s sale of an invention to a third party that was obligated to keep the invention confidential qualified as prior art for purposes of determining the patentability of the invention. Justice Clarence Thomas wrote on behalf of the unanimous Court.

In reaching its decision, the Court noted that every patent statute since 1836 has included an on-sale bar. It also emphasized that its own precedent interpreting the pre-AIA on-sale bar provision supports the view that a sale or offer of sale need not make an invention available to the public to constitute invalidating prior art. “The Federal Circuit—which has ‘exclusive jurisdiction’ over patent appeals, 28 U. S. C. §1295(a)—has made explicit what was implicit in our precedents,” Justice Thomas added. “It has long held that ‘secret sales’ can invalidate a patent.”

The Court further concluded that the catch-all phrase “or otherwise available to the public” did not alter its conclusion. Justice Thomas explained:

As amicus United States noted at oral argument, if “on sale” had a settled meaning before the AIA was adopted, then adding the phrase “or otherwise available to the public” to the statute “would be a fairly oblique way of attempting to overturn” that “settled body of law.” Tr. of Oral Arg. 28. The addition of “or otherwise available to the public” is simply not enough of a change for us to conclude that Congress intended to alter the meaning of the reenacted term “on sale.”

Key Takeaway

The Supreme Court’s decision makes it even more imperative for businesses to thoroughly review the structure of joint ventures and other development deals with an experienced intellectual property attorney to verify that the agreements can’t later be interpreted as an offer to sell a later-patented invention. As highlighted by the Court’s ruling, simply including confidentiality provisions in such agreements won’t shield the invention from invalidation under the on-sale bar. 

If you have questions, please contact us

If you have any questions or if you would like to discuss the matter further, please contact me, David A. Einhorn, at 201-806-3364.

Let`s get in touch!

* The use of the Internet or this form for communication with the firm or any individual member of the firm does not establish an attorney-client relationship. Confidential or time-sensitive information should not be sent through this form.

Sign up to get the latest from the Scarinci Hollenbeck, LLC attorneys!

Please select a category(s) below: